Prolytic GmbH - Independent laboratory - GLP/GCP

History

The roots of Prolytic GmbH can be traced back to ASTA Medica AG, a pharmaceutical research company and formerly wholly owned subsidiary of Degussa AG.

The new owner of Degussa, e.on AG, focused its business strategy mainly on energy and chemistry and thus decided to divest ASTA Medica splitting it up into different business units.

The biggest unit, Viatris GmbH & Co. KG, was sold to a finance investor whose new philosophy did not include the drug development sections “Bioanalysis” and “Pharmacokinetics.” Therefore, with the help of the management of Viatris GmbH & Co. KG, which provided the necessary equipment, an experienced group of scientists from these sections founded Prolytic GmbH in December 2002 with the aim of offering their abundant experience in bioanalysis and pharmacokinetics to clients in the pharmaceutical sector.

Our Goal

Our long-standing experience in chemical analysis and pharmacokinetics is the basis for high-quality bioanalytics, competent advice, and absolute reliability.

Due to our highly-qualified employees, we are able to guarantee exact results according to tight time schedules.

Our expertise enables us to advise our clients competently and to work on complex assignments in an efficient and cost-effective manner.
In addition to bioanalysis, we provide pharmacokinetic evaluation and expert reports. Furthermore, through cooperation with our partner companies we are able to extend the range of services we can offer our clients.

In line with the slogan “all under one roof,” we conduct complete kinetic studies.

Of course, our laboratory is GLP-certified so that we are able to provide all services falling under the categories 1 and 8.

For a detailed overview of our services offers please go to Services.

The Management

Dorothee Krone Prolytic GmbH

Dorothee Krone, Dr. phil. nat.

Managing Director

Dorothee Krone began her career in 1992 as a chemical engineer at Asta Medica AG. There, she became head of labortory for bioanalysis, preclinical development (ADME studies) and pharmacokinetics. During that time she accomplished an Industrial Engineer Degree as well as her Ph.D at the University of Frankfurt working together with the University of Florida in Gainesville.

Since the foundation in 2003 Dr. Krone is Managing Director and Shareholder of Prolytic GmbH.

E-Mail: dorothee.krone[at]prolytic.de